High-dosage anticoagulants did not significantly reduce 28-day mortality compared to low-dosage therapy in patients with acute myocardial infarction (16.2% vs 18.0%).
RCT (n=1,427)
Random
Tasa de eventos absoluta: 16.2% vs 18%
This report describes the design and results of a controlled trial of anticoagulant drugs in the treatment of patients admitted to hospital suffering from acute myocardial infarction. A total of 1,427 patients were allocated at random to therapy with high-dosage or low-dosage anticoagulants. The high-dosage regimen was 36 hours of heparin administration and phenindione in doses to maintain the thrombotest level between 10 and 20%. The mean phenindione dosage was 72 mg./day. The low-dosage regimen consisted of 1-mg. tablets of phenindione. Therapy was continued for 28 days. There was no significant reduction in the mortality in the high-dosage group. Among the 712 patients allocated to high dosage 115 (16·2%) died before the 29th day of the trial. Of the 715 patients allocated to low dosage 129 (18%) died. This difference between these mortality rates could have occurred by chance. There was a significant reduction in the frequency of clinically evident thromboembolic complications (systemic artery occlusion, leg vein thrombosis, and pulmonary embolism) among patients in the high-dosage group. This did not, however, materially affect the difference in mortality from all causes.
A Sat, study conducted a rct in Acute myocardial infarction (n=1,427). High-dosage anticoagulants (heparin and phenindione) vs. Low-dosage anticoagulants (1-mg tablets of phenindione) was evaluated on Mortality before the 29th day. High-dosage anticoagulants did not significantly reduce 28-day mortality compared to low-dosage therapy in patients with acute myocardial infarction (16.2% vs 18.0%).